Monopar TherapeuticsMNPR
13F holders, Q2 2024 (June 30)12holders −4
1new positions
5sold out
1famous investor
$0.74avg. 13F price*
At the end of Q2 2024, 12 institutions reported holding Monopar Therapeutics Inc. (MNPR) in their 13F filings, down 4 from Q1 2024. 1 opened new positions and 5 sold out. The largest holders were Millennium Management ($145K), Geode Capital Management, LLC ($45K) and Two Sigma Securities, LLC ($34K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Monopar Therapeutics Inc.
- CUSIP
- 61023L108
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $34K |
| Exits | 5 | $27K |
All 13F filers, Q1 2024 → Q2 2024: 68,902 shares bought and 46,068 shares sold, net +22,834 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Millennium Management | 0.00% | Add +1.0% | 194,298 | $145K |
| Geode Capital Management, LLC | 0.00% | Add +45.7% | 60,036 | $45K |
| Two Sigma Securities, LLC | 0.00% | New | 47,058 | $34K |
| Vanguard Group Inc. | 0.00% | No change | 45,167 | $33K |
| Gerber, LLC | 0.02% | No change | 28,005 | $20K |
| Virtu Financial LLC | 0.00% | Reduce -20.9% | 18,840 | $14K |
| Rappaport Reiches Capital Management, LLC | 0.00% | No change | 10,695 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.8% | 7,922 | $6K |
| NewEdge Advisors, LLC | 0.00% | No change | 3,000 | $2K |
| Wells Fargo & Company | 0.00% | Add +62.6% | 2,500 | $2K |
| Bank of America Corp. | 0.00% | Add +12.2% | 561 | $410 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 80 | $58 |
"% of holder's portfolio" is MNPR's weight in each manager's 13F, not the share of Monopar Therapeutics Inc. the manager owns.